1. Home
  2. KRP vs KARD Comparison

KRP vs KARD Comparison

Compare KRP & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kimbell Royalty Partners

KRP

Kimbell Royalty Partners

N/A

Current Price

$15.42

Market Cap

1.4B

Sector

Energy

ML Signal

N/A

Logo Kardigan Inc. Common Stock

KARD

Kardigan Inc. Common Stock

N/A

Current Price

$14.27

Market Cap

1.5B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
KRP
KARD
Founded
2013
2023
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Sector
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.5B
IPO Year
2017
2026

Fundamental Metrics

Financial Performance
Metric
KRP
KARD
Price
$15.42
$14.27
Analyst Decision
Buy
Strong Buy
Analyst Count
6
9
Target Price
$19.20
★ $41.13
AVG Volume (30 Days)
★ 839.8K
513.7K
Earning Date
11-05-2026
11-12-2026
Dividend Yield
★ 10.29%
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
★ $333,830,000.00
N/A
Revenue This Year
$23.40
N/A
Revenue Next Year
$2.71
$50.00
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 7.93
N/A
52 Week Low
$11.31
$12.23
52 Week High
$17.12
$27.00

Technical Indicators

Market Signals
Indicator
KRP
KARD
Relative Strength Index (RSI) 45.06 48.64
Support Level $14.54 $13.75
Resistance Level $15.56 $15.93
Average True Range (ATR) 0.36 1.21
MACD -0.19 0.26
Stochastic Oscillator 25.67 47.78

Price Performance

Historical Comparison
KRP
KARD

About KRP Kimbell Royalty Partners

Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.

About KARD Kardigan Inc. Common Stock

Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.

Share on Social Networks: